Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 6/20 | 0.33 |
| ▸ | GAA | P10253 | 6/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.33 |
| ▸ | NPC1 | O15118 | 4/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.32 |
| ▸ | HTT | P42858 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 4/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10845741 | 1.00 | CYP2C19 (0.36) | CYP2C19MEN1GAAKMT2ANPC1 | |
| Methane SCHEMBL28061561 | 0.99 | CYP2C19 (0.35) | CYP2C19MEN1GAAKMT2ANPC1 | |
| SCHEMBL11208659 | 0.80 | PPARG (0.40) | GAAKMT2ANPC1ITGB1ITGA4 | |
| SCHEMBL11208660 | 0.80 | PPARG (0.40) | GAAKMT2ANPC1ITGB1ITGA4 | |
| SCHEMBL4519604 | 0.78 | MME (0.36) | — | |
| SCHEMBL14547050 | 0.77 | GAA (0.38) | MEN1GAAKMT2ANPC1HSD17B10 | |
| SCHEMBL9956549 | 0.76 | ALDH1A1 (0.33) | CYP2C19KMT2ANPC1HSD17B10MAPT | |
| SCHEMBL9956545 | 0.76 | ALDH1A1 (0.33) | CYP2C19KMT2ANPC1HSD17B10MAPT | |
| Benzene SCHEMBL27792631 | 0.76 | CPB2 (0.35) | SMN1; SMN2 | |
| SCHEMBL7607068 | 0.76 | MME (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 392 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109988312-A | A kind of poly amic acid ester, preparation method and negative polyimide composition and application | 深圳先进技术研究院 | 2019-07-09 | — | — | CN | claimed |
| CN-109946925-A | A kind of compound is promoting the application in polyimides low-temperature setting, polyimide precursor composition and application thereof | 深圳先进技术研究院 | 2019-06-28 | — | — | CN | claimed |
| CN-102596915-B | The synthetic method of 2-thiolhistidine and analogue | TETRAHEDRON (FR) | 2016-04-20 | — | — | CN | claimed |
| US-20090281093-A1 | ANTI-INFLAMMATORY COMPOUNDS | C.T.G. PHARMA S.R.L. (IT) | 2009-11-12 | — | — | US | claimed |
| US-20090275539-A1 | Nuclear Transcription Factors Regulators | CTG PHARMA S.R.L. (IT) | 2009-11-05 | — | — | US | claimed |
| US-20090227597-A1 | PYRAZOLOPYRIMIDINONES AS PHOSPHODIESTERASE INHIBITORS | CTG PHARMA S.R.L. (IT) | 2009-09-10 | — | — | US | claimed |
| US-20080207751-A1 | Sulindac Derivatives for Treatment of Cancer | SULFIDRIS S.R.L. (IT) | 2008-08-28 | — | — | US | claimed |
| EP-1904440-A1 | SULINDAC DERIVATIVES FOR TREATMENT OF CANCER | Sulfidris S.r.l. (IT) | 2008-04-02 | — | — | EP | claimed |
| EP-1871360-A1 | NEW ANTI-INFLAMMATORY COMPOUNDS | CTG Pharma S.r.l. (IT) | 2008-01-02 | — | — | EP | claimed |
| WO-2006134489-A1 | SULINDAC DERIVATIVES FOR TREATMENT OF CANCER | SULFIDRIS S.R.L. (IT) | 2006-12-21 | — | — | WO | claimed |
| WO-2006111791-A1 | NEW ANTI-INFLAMMATORY COMPOUNDS | CTG PHARMA S.R.L. (IT) | 2006-10-26 | — | — | WO | claimed |
| WO-2006037623-A2 | NEW NUCLEAR TRANSCRIPTION FACTORS REGULATORS | CTG PHARMA S.R.L. (IT) | 2006-04-13 | — | — | WO | claimed |
| EP-1645288-A1 | New nuclear transcription factors regulators | CTG Pharma S.r.l. (IT) | 2006-04-12 | — | — | EP | claimed |
| EP-1630164-A1 | Pyrazolopyrimidinones as phosphodiesterase inhibitors | Expotrend Company SA (CH) | 2006-03-01 | — | — | EP | claimed |
| WO-1995029930-A2 | IMPROVED METHOD FOR OLIGONUCLEOTIDE ANALOG SYNTHESIS | GILEAD SCIENCES, INC. (US) | 1995-11-09 | — | — | WO | claimed |
| JP-58216192-A | — | — | None | — | — | JP | disclosed |
| JP-58219186-A | — | — | None | — | — | JP | disclosed |
| JP-S58219186-A | NOVEL CEPHALOSPORIN | ASAHI CHEM IND CO LTD | 1983-12-20 | — | — | JP | disclosed |
| JP-S58216192-A | NOVEL PENICILLIN COMPOUND | ASAHI CHEM IND CO LTD | 1983-12-15 | — | — | JP | disclosed |
| EP-0068403-A2 | Cephalosporin compound | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207751-A1 | Sulindac Derivatives for Treatment of Cancer | PTGES3, PTGES2, PTGS1 | CYP2C19 1065/4885MEN1 4677/4885GAA 4624/4885 |
| US-20090227597-A1 | PYRAZOLOPYRIMIDINONES AS PHOSPHODIESTERASE INHIBITORS | PDE3A, PDE3B, PDE2A | CYP2C19 199/4885MEN1 3037/4885GAA 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.